Billionaire David Tepper Goes All-In on AI Infrastructure Bets
The 13F filings show billionaire david tepper goes big on Alphabet, Micron, and Meta, while dialing back on Alibaba a...
Investing
Learn smart investing strategies for stocks, ETFs, bonds, and building long-term wealth.
8,001 articles
March Brings Social Security Shake-Up to Millions Now
On March 7, Social Security moves to nationwide support, risking longer waits as offices consolidate. The shift could...
ETFs for 2028 White House Bets Roar Across Markets
Roundhill unveiled plans for a suite of ETFs that would track prediction-market odds on the 2028 U.S. election, signa...
How Retirees with Save $100,000+ Cut Lifetime Taxes
A growing cohort of retirees with nest eggs between $800k and $2M can meaningfully reduce lifetime tax bills through ...
Nancy Pelosi Buys Bullish Calls on Amazon as Buffett Sells
In a striking contrast, Nancy Pelosi buys bullish calls on Amazon as Berkshire Hathaway scales back its Amazon exposu...
Investor Gavin Baker Bets Big on Nvidia with Calls
In a bold move amid 13F season, investor Gavin Baker places a major levered bet on Nvidia through call options, signa...
NVIDIA Just Deliver Crushing Blow Clouds AMD Outlook
NVIDIA’s new alliance with Meta Platforms tightens the AI infrastructure backbone, pushing AMD to the back foot as in...
XOVR: A $1.5 Billion ETF with Pre-IPO SpaceX Exposure
XOVR, the $1.5 billion ETF that blends pre-IPO SpaceX exposure with public-growth stocks, is drawing renewed scrutiny...
Palo Alto Networks Drops 6.5% as Q3 Guidance Misses
Palo Alto Networks fell sharply after reporting a solid Q2 on earnings but guiding Q3 profits below expectations. The...
Warren Buffett’s Final Investment Signals Full Circle
As Berkshire transitions to Greg Abel, Warren Buffett’s final investment points to a return to era-defining brands. T...
Tempus Stock Today What Sparks Rally Ahead of Earnings
Tempus AI shares rose as it introduced an AI-powered HRD-RNA cancer diagnostic algorithm, signaling momentum before i...
XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...